Multiple sclerosis recent modalities of treatment

Multiple sclerosis [MS] has devastating physical, psychological, and economic consequences. The disease commences in most patients with a relapsing-Dremitting course, and it is likely that treatment is most effective during this phase before permanent axon damage has occurred. Despite the absence of a cure for MS, the 4 available drug therapies [Interferon [IFN] section -1a, IFN section -1b, glatiramer acetate, and mitoxantrone] play a role in the management of MS based on their demonstrated efficacy. In particular, the use of disease-modifying drugs has been shown to reduce the frequency and severity of debilitating relapses and to delay disease progression. Efforts to develop alternative therapies with increased efficacy and patient acceptability are in progress

Imaging findings of neuro-Behcet disease

To study the neuroimaging findings of neuro-Behcet's disease [NBD] in Saudi patients and to discuss the radiological differential diagnosis. The clinical data and radiological findings on CT, MRI and cerebral angiography of 16 patients with NBD attending King Khalid University Hospital, Riyadh, Kingdom of Saudi Arabia, from January 1990 to February 2003 were reviewed. Out of 16 patients with NBD, 11 patients [68.75%] had cerebral venous thrombosis predominantly involving superior sagittal sinus causing intracranial hypertension, while 5 patients [31.25%] had symptoms and signs related to brain parenchymal involvement predominantly affecting brainstem. Pattern of distribution of brain parenchymal lesions in NBD might help to differentiate it from other vasculitides as well as from demyelinating disease such as multiple sclerosis. Cerebral venous thrombosis is a common manifestation of NBD